TNP-2092 is under clinical development by TenNor Therapeutics and currently in Phase III for Bacterial Infections. According to GlobalData, Phase III drugs for Bacterial Infections have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how TNP-2092’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TNP-2092 (CBR-2092) is under development for the treatment of acute bacterial skin and skin structure infection, prosthetic joint infections, biofilm-associated bacterial infections, hepatic encephalopathy, cirrhosis, irritable bowel syndrome, diarrhea, hyperammonemia, and gastrointestinal tract infections including Helicobacter pylori Infections, superbug and diabetic foot infections.. The drug candidate is administered through oral and intravenous route. It is a rifamycin-quinolone based hybrid antibiotic. The drug candidate is a small molecule which acts by targeting RNA polymerase, DNA gyrase and DNA topoisomerase IV. It was also under development for bacterial infections.
TenNor Therapeutics overview
TenNor Therapeutics develops novel drugs for the treatment of infectious diseases. The company’s pipeline Product portfolio includes TNP-2092 IV for the treatment of prosthetic joint infections (PJI); TNP-2092 PO for gastrointestinal tract infections; TNP-2198 for the treatment of bacterial vaginosis and anaerobic infections; MDR-TB for tuberculosis; and MDR-GN for the treatment of infections caused by multidrug resistant gram-negative bacteria. It also carries out research and development activities for developing new drugs. TenNor Therapeutics has collaborations with 3D Bio Optima, Colorado State University, JMI Laboratories, Peking University, and others. The company has operational presence across the globe. TenNor Therapeutics is headquartered in Suzhou, Jiangsu, China.
For a complete picture of TNP-2092’s drug-specific PTSR and LoA scores, buy the report here.